Influence of Internal Structure and Composition of Liquid Crystalline Phases on Topical Delivery of Paclitaxel

Hosmer, Jaclyn; Shin, Soo Hyeon; Nornoo, Adwoa O.; Zheng, Haian; Lopes, Luciana B.

doi:10.1002/jps.22370

Cited by 52 publications

(33 citation statements)

References 44 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using this method, drug recovery from skin layers was within 85%-93%. 7 Paclitaxel delivered into SC, ED, and receptor phase was assayed by high-performance liquid chromatography (HPLC) after sample filtration (0.45 µm pore PTFE membranes). The assay was performed using a Shimadzu Prominence HPLC system equipped with a pump model LC-20AB, an autosampler model SIL-20A, a photodiodoarray detector model SPD-M20A set at 228 nm, and a Phenomenex C18 column (maintained at 25°C).…”

Section: In Vitro Skin Penetrationmentioning

confidence: 99%

“…[4][5][6] Thus, nanocarriers capable of improving paclitaxel cutaneous localization while limiting its transdermal permeation could potentially allow the use of this drug for the treatment of skin tumors. 3,5,7,8 In this context, this study was aimed at evaluating the cutaneous delivery, safety, and efficacy of paclitaxel nanocarriers in bioengineered models of healthy and tumor-containing skin.…”

Section: Introductionmentioning

confidence: 99%

“…3,[7][8][9][10] Thus, in the first part of this study, the ability of a selected nanocarrier to improve the amount of drug delivered into skin layers was optimized. Microemulsions (MEs) were selected as nanocarriers due to their simple preparation (since there is no special requirement in terms of energy supply), thermodynamic stability, and versatility of composition, which can reduce costs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel

Pepe¹,

Carvalho²,

Mccall³

et al. 2016

IJN

View full text Add to dashboard Cite

In this study, the ability of nanocarriers containing protein transduction domains (PTDs) of various classes to improve cutaneous paclitaxel delivery and efficacy in skin tumor models was evaluated. Microemulsions (MEs) were prepared by mixing a surfactant blend (polyoxyethylene 10 oleoyl ether, ethanol and propylene glycol), monocaprylin, and water. The PTD transportan (ME-T), penetratin (ME-P), or TAT (ME-TAT) was added at a concentration of 1 mM to the plain ME. All MEs displayed nanometric size (32.3–40.7 nm) and slight positive zeta potential (+4.1 mV to +6.8 mV). Skin penetration of paclitaxel from the MEs was assessed for 1–12 hours using porcine skin and Franz diffusion cells. Among the PTD-containing formulations, paclitaxel skin (stratum corneum + epidermis and dermis) penetration at 12 hours was maximized with ME-T, whereas ME-TAT provided the lowest penetration (1.6-fold less). This is consistent with the stronger ability of ME-T to increase transepidermal water loss (2.4-fold compared to water) and tissue permeability. The influence of PTD addition on the ME irritation potential was assessed by measuring interleukin-1α expression and viability of bioengineered skin equivalents. A 1.5- to 1.8-fold increase in interleukin-1α expression was induced by ME-T compared to the other formulations, but this effect was less pronounced (5.8-fold) than that mediated by the moderate irritant Triton. Because ME-T maximized paclitaxel cutaneous localization while being safer than Triton, its efficacy was assessed against basal cell carcinoma cells and a bioengineered three-dimensional melanoma model. Paclitaxel-containing ME-T reduced cells and tissue viability by twofold compared to drug solutions, suggesting the potential clinical usefulness of the formulation for the treatment of cutaneous tumors.

show abstract

Section: In Vitro Skin Penetrationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel

Pepe¹,

Carvalho²,

Mccall³

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…178 Hosmer et al in 2012, studied mesophase lamellar LCs formed with glycerides for the incorporation of the anticancer drug paclitaxel. 184 Paclitaxel is highly effective against various types of cancer, including oral cancer; [185][186][187] however, it has severe adverse effects associated with systemic drug administration, including hypersensitivity reactions, thrombocytopenia, and neutropenia. 188,189 Hosmer et al 184 found that, among the formulations studied, the Brij-based lamellar phase containing 20% medium-chain …”

Section: Liquid Crystalsmentioning

confidence: 99%

Nanotechnology-based drug delivery systems for treatment of oral cancer: a review

Calixto¹,

Fonseca-Santos²,

Chorilli³

et al. 2014

IJN

151

View full text Add to dashboard Cite

Oral cancer (oral cavity and oropharynx) is a common and aggressive cancer that invades local tissue, can cause metastasis, and has a high mortality rate. Conventional treatment strategies, such as surgery and chemoradiotherapy, have improved over the past few decades; however, they remain far from optimal. Currently, cancer research is focused on improving cancer diagnosis and treatment methods (oral cavity and oropharynx) nanotechnology, which involves the design, characterization, production, and application of nanoscale drug delivery systems. In medicine, nanotechnologies, such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, gold nanoparticles, hydrogels, cyclodextrin complexes, and liquid crystals, are promising tools for diagnostic probes and therapeutic devices. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for oral cancers.

show abstract

“…54 Paclitaxel (PTX) is a highly hydrophobic macrocyclic, that can accumulate within the SC and does not penetrate into the deeper skin layers. 55,56 Currently, PTX is intravenously administered as Taxol ® (Bristol-Myers Squibb Company, Princeton, NJ, USA), in a Cremophor EL ® (BASF SE, Limburgerhof, Germany) and ethanol (50%:50% v/v) formulation, or Abraxane ® (Celgene Corporation, Summit, NJ, USA) in an albumin nanoparticle formulation. In agreement with that observed for other hydrophobic compounds, 34 PTX was homogeneously distributed in the hydroethanolic and hydrophobic compartments of the ethosomes.…”

mentioning

confidence: 99%

Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations

Romero¹,

Morilla²

2013

IJN

View full text Add to dashboard Cite

Vesicles that are specifically designed to overcome the stratum corneum barrier in intact skin provide an efficient transdermal (systemic or local) drug delivery system. They can be classified into two main groups according to the mechanisms underlying their skin interaction. The first group comprises those possessing highly deformable bilayers, achieved by incorporating edge activators to the bilayers or by mixing with certain hydrophilic solutes. The vesicles of this group act as drug carriers that penetrate across hydrophilic pathways of the intact skin. The second group comprises those possessing highly fluid bilayers, owing to the presence of permeation enhancers. The vesicles of this group can act as carriers of drugs that permeate the skin after the barrier of the stratum corneum is altered because of synergistic action with the permeation enhancers contained in the vesicle structure. We have included a detailed overview of the different mechanisms of skin interaction and discussed the most promising preclinical applications of the last five years of Transfersomes ® (IDEA AG, Munich, Germany), ethosomes, and invasomes as carriers of antitumoral and anti-inflammatory drugs applied by the topical route.

show abstract

Influence of Internal Structure and Composition of Liquid Crystalline Phases on Topical Delivery of Paclitaxel

Cited by 52 publications

References 44 publications

Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel

Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel

Nanotechnology-based drug delivery systems for treatment of oral cancer: a review

Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations

Contact Info

Product

Resources

About